All In Biotech

NDA 014901 · Apothecon

Kenalog-40

Triamcinolone Acetonide · Injection · Corticosteroid

Last checked: Nov 20, 2026Latest source record: Aug 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1965

Feb 1, 1965

Approved uses

1

Original approval plus efficacy supplements

Registered trials

692

135 Phase 3, 52 recruiting

FAERS reports

26,375

13,659 serious, 3,186 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 5, 2026.

INDICATIONS AND USAGE Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including KENALOG-40 Injection and KENALOG-80 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 1, 1965 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • KENALOG-40 · TRIAMCINOLONE ACETONIDE 40MG/ML · INJECTABLE, INJECTION · Prescription · TE AB
  • KENALOG-80 · TRIAMCINOLONE ACETONIDE 80MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Triamcinolone Acetonide" as an intervention, any sponsor and status, largest first.

All 692 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,884
  • off label use2,930
  • pruritus2,762
  • rash2,589
  • pain2,199
  • fatigue2,074
  • nausea1,988
  • product use in unapproved indication1,770
  • diarrhoea1,720
  • vomiting1,716
  • headache1,688
  • condition aggravated1,682

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004145
2005141
2006181
2007146
2008232
2009191
2010195
2011293
2012206
2013228
2014368
2015600
2016789
2017970
20181,175
20191,313
20201,533
20211,813
20222,342
20232,752
20243,567
20253,888
20263,307

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kenalog-40 (Triamcinolone Acetonide)

2024 spending

$18K

Beneficiaries

685

867 claims

Per beneficiary

$27

$1.87 per unit

View as table
YearSpending
2020$63,589
2021$40,631
2022$35,135
2023$25,718
2024$18,291

Part D: Kenalog-80 (Triamcinolone Acetonide)

2024 spending

$16K

Beneficiaries

363

492 claims

Per beneficiary

$44

$20.63 per unit

View as table
YearSpending
2020$6,305
2021$9,556
2022$13,293
2023$10,305
2024$16,067

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 993 on PubMed

Sponsor: Apothecon · Also marketed as Kenalog-80

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.